Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 145 versus ezetimibe in statin-intolerant hypercholesterolemic subjects
2013-000935-29Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evolocumab in hypercholesterolemia (2 arms), sponsored by Amgen. Primary endpoint: Percent change from baseline in LDL-C. Started Nov 2013; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2013-000935-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000935-29.